Investor Relations

Cassava Sciences, Inc. is a biopharmaceutical company that develops novel drugs.

Presentations

Financial Information

Press Releases

Cassava Sciences Initiates Phase 2b Clinical Study in Alzheimer’s Patients

Sep 16, 2019

First two patients dosed with lead drug candidate, PTI-125 Study initiation follows positive Phase 2a results demonstrating 100% response rate AUSTIN, Texas , Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biopharmaceutical company focused on

Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimer’s Patients

Sep 09, 2019

Lead drug candidate, PTI-125, significantly decreased key biomarkers of neuroinflammation and neurodegeneration in all study patients (p<.001 clinical="" data="" support="" initiation="" of="" a="" phase="" study="" in="" alzheimer="" q3="" austin="" texas="" sept.="" newswire="" cassava="" sciences="" inc.="">

View all